LianBio (NASDAQ: LIANY) is a clinical-stage biopharmaceutical company that in-licenses drug candidates from global partners for development and commercialization in China and other Asian markets. The company generates no product revenue, operating entirely on licensed assets while funding operations through equity raises. LianBio reported a net loss of $110.3 million for the year ended December 31, 2022, down from a net loss of $196.3 million for the year ended December 31, 2021. Research and development expenses were $59.8 million and general and administrative expenses were $65.6 million for the year ended December 31, 2022. The company had no revenue-generating products as of the filing date, with cash used in operating activities of $99.2 million in FY2022. LianBio operates under China's medical device and pharmaceutical regulatory framework, including oversight by the SAMR and relevant Medical Product Administrations.

Revenue model

LianBio had no product revenue as of the 10-K filed March 28, 2023. Operations are funded through equity financing. Interest income of $4.3 million and other income of $10.4 million were recorded for the year ended December 31, 2022.

Products and services

LianBio holds in-licensed clinical-stage drug candidates targeting oncology indications. Clinical data disclosed in the filing references a program with a BICR-assessed objective response rate of 23.1% (95% CI: 15.6-32.2) in a full analysis set of 108 patients. No approved or commercialized products are identified in the filing excerpts.

Customers and end markets

End markets are oncology patients in China and other Asian markets. No commercial customers or revenue-generating relationships are identified in the filing excerpts as of the year ended December 31, 2022.

Value-chain role

LianBio functions as a regional licensee, acquiring rights to drug candidates from global biopharmaceutical partners and conducting clinical development within China. The company does not manufacture products and relies on entrusted manufacturers subject to Chinese regulatory requirements including Order 53 and Order 54.

Geographic exposure

Operations are focused on China, with regulatory compliance obligations under Chinese authorities including the SAMR and Medical Product Administrations. Data storage and whistleblower systems involve servers in the United States, Mainland China, and Hong Kong.

Source: SEC 10-K, filed 2023-03-28

Industry: Pharmaceutical Preparations Peers: 89bio, Inc. Evelo Biosciences, Inc. Kronos Bio, Inc. Rigel Pharmaceuticals Inc Cartesian Therapeutics Inc Shuttle Pharmaceuticals Holdings Inc Voyager Therapeutics Inc